NMT Medical, Inc. Assigned All Its Assets to Joseph F. Finn, Jr., C.P.A. of the Firm Finn, Warnke & Gayton, LLP on April 20, 2011

WELLESLEY HILLS, Mass., May 3, 2011 /PRNewswire-Asia/ -- On April 20, 2011, NMT Medical, Inc. ("NMT Medical") assigned all its assets to Joseph F. Finn, Jr., C.P.A. ("Finn") of the firm Finn, Warnke & Gayton, LLP to be liquidated for the benefit of NMT Medical creditors.

NMT Medical's intellectual property consists of:

• CLOSURE I Clinical Trial Data;

• MIST and MIST II Clinical Trial Data;

• CardioSEAL®, STARFlex®, and BioSTAR® Technologies for Septal Defect Repair;

• BioTREK™ Bioabsorbable Technology for Intracardiac Defect Closure, and

• Alternative Technologies for Intracardiac  Defect Closure

The intellectual property, patents, etc. will be sold at a sealed bid sale on Friday, June 10, 2011 at noon.  Persons interested in bidding must sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's Office – jffinnjr@finnwarnkegayton.com or 781-237-8840.  They will then receive a bid package.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A. is a founding partner of the firm Finn, Warnke & Gayton (www.finnwarnkegayton.com), Certified Public Accountants of Wellesley Hills, Massachusetts.  He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation.  He has been involved in a number of loan workouts and bankruptcy cases for thirty-five (35) years.  His most recent Assignments for the Benefit of Creditors in the biotech field include Spherics, Inc., ActivBiotics, Inc., Prospect Therapeutics, Inc., EPIX Pharmaceuticals, Inc. and Source MDx.

For further information, please contact:

Joseph F. Finn
Jr., C.P.A.
Phone: +1-781-237-8840
Email: jffinnjr@finnwarnkegayton.com